ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Investors raised $75 million to form ProKidney to develop kidney stem-cell therapies

by Ryan Cross
January 27, 2019 | APPEARED IN VOLUME 97, ISSUE 4

 

Pablo Legorreta, founder and CEO of Royalty Pharma, an investment firm that acquires pharmaceutical royalty streams, has led a group of investors in founding a new company called ProKidney. After raising $75 million, ProKidney spent $62 million to acquire the cell ­therapy company inRegen and its ­manufacturing affiliate, Twin City Bio. inRegen is developing therapies for kidney diseases using stem cells obtained and isolated from a biopsy. Those cells are grown in the lab and implanted back into the damaged kidney on a hydrogel scaffold. Phase II trials are underway.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment